Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to characterize the pharmacokinetics (absorption, distribution, metabolism, and excretion; ADME) and oral bioavailability of tartaric acid in humans after its administration through different food matrices (red wine, fresh grapes, and grape juice). The study aims to determine whether the pharmacokinetic behavior of tartaric acid is matrix-dependent and dose-dependent in healthy adult volunteers.
The main questions it aims to answer are:
Does the food matrix (wine, grapes, or grape juice) influence the oral bioavailability of tartaric acid?
Are there differences in key pharmacokinetic parameters of tartaric acid, including maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), total exposure (AUC), half-life (t1/2), and urinary excretion, depending on the matrix of intake?
Researchers will compare the pharmacokinetic profiles of tartaric acid after consumption in red wine, grapes, and grape juice to evaluate differences in absorption, systemic exposure, and elimination attributable to the source of intake.
Participants will:
Follow a polyphenol-restricted diet prior to the study, including avoidance of grapes, wine, and related products.
Consume a single standardized dose of tartaric acid administered as red wine, fresh grapes, or grape juice after an overnight fast.
Provide blood samples at multiple time points over a 24-hour period to determine plasma tartaric acid concentrations.
Collect urine samples over 24 hours for assessment of tartaric acid excretion.
Consume standardized low-polyphenol meals under controlled conditions during the study day.
This study will characterize the pharmacokinetics (absorption, distribution, metabolism, and excretion) and oral bioavailability of tartaric acid (TA) in humans after consumption in different food matrices: red wine, fresh grapes, and grape juice. Although moderate wine consumption has been associated with cardiometabolic benefits, the human pharmacokinetics of TA-the main organic acid in grapes and wine-remain largely uncharacterized. Existing data from animal studies do not account for the influence of the food matrix on absorption or systemic exposure.
TA has been proposed as an objective biomarker of wine intake, and its dietary presence may contribute to observed cardiovascular and anti-inflammatory effects. Bioavailability of bioactive compounds is strongly matrix-dependent, and interactions within complex foods can enhance or limit absorption. This study provides the first direct evaluation of whether TA pharmacokinetics differ depending on the food matrix.
Using a randomized, parallel-group design, participants will receive a standardized dose of TA in one of the three matrices, with plasma and urine samples analyzed by advanced LC-MS/MS methods. Results will establish reference pharmacokinetic parameters, clarify the effect of the food matrix on TA bioavailability, and support development of functional grape-derived products, while improving interpretation of epidemiological evidence linking TA to cardiometabolic health.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Red Wine | Experimental | Participants will consume 100 mL of red wine, providing a standardized dose of tartaric acid, after a 10-hour overnight fast. The wine will be ingested within 5 minutes, accompanied by a standardized meal (2 slices of white bread) to simulate real-life consumption conditions. Intake of other fluids will be controlled (water ad libitum except during the first hour), and compliance will be monitored through direct observation. |
|
| Grape fruits | Experimental | Participants will consume a portion of fresh grapes containing an equivalent dose of tartaric acid to the wine, following the same controlled conditions: after a 10-hour overnight fast, ingested within 5 minutes with the standardized meal, with controlled fluid intake and direct compliance monitoring. |
|
| Grape juice | Experimental | Participants will consume 150 mL of grape juice standardized for tartaric acid content, under identical conditions: after a 10-hour overnight fast, ingested within 5 minutes with the standardized meal, with controlled fluid intake and compliance monitoring. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Wine | Dietary Supplement | 100 mL of red wine containing a standardized dose of tartaric acid, ingested after a 10-hour overnight fast with a standardized meal (2 slices of white bread). Consumption completed within 5 minutes, fluid intake controlled, compliance monitored. |
| Measure | Description | Time Frame |
|---|---|---|
| Oral bioavailability of tartaric acid | Quantification of the oral bioavailability of tartaric acid after administration in different dietary matrices (wine, grape, grape juice) using dose-response studies. | 0-24 hours post-ingestion |
| Maximum plasma concentration (Cmax) | Determination of the peak plasma concentration of tartaric acid in human plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). | 0-24 hours, sampling at 0, 15, 30 min, 1, 2, 3, 4, 6, 8, and 24 h post-ingestion |
| Time to reach maximum plasma concentration (Tmax) | Time required to reach the Cmax of tartaric acid in plasma. | 0-24 hours, sampling at 0, 15, 30 min, 1, 2, 3, 4, 6, 8, and 24 h post-ingestion |
| Area under the plasma concentration-time curve (AUC) | Total plasma exposure of tartaric acid determined by non-compartmental analysis using WinNonlin. | 0-24 hours, sampling at 0, 15, 30 min, 1, 2, 3, 4, 6, 8, and 24 h post-ingestion |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma half-life (t1/2) | Time required to reduce plasma tartaric acid concentration by half, calculated using non-compartmental analysis. | 0-24 hours, sampling at 0, 15, 30 min, 1, 2, 3, 4, 6, 8, and 24 h post-ingestion |
| Maximum cumulative urinary concentration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anallely López Yerena, PI | Contact | 932275400 | 2907 | nayelopezye@ub.edu |
| Rosa M. Lamuela-Raventós, Co-PI | Contact | Lamuela-Raventós | lamuela@ub.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Internal Medicine, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer | Barcelona | Barcelona | 08036 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014920 | Wine |
| C000722782 | whole grape extract |
| ID | Term |
|---|---|
| D000434 | Alcoholic Beverages |
| D001628 | Beverages |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
This is a randomized, partially blinded, interventional study designed to evaluate the effects of different polyphenol-containing matrices on healthy adults. Thirty healthy non-smoking participants (aged 20-40 years, BMI 23-27 kg/m²), without a history of cardiovascular, hepatic, or renal disease, and not following any special diet for at least 4 weeks prior to the study, will be recruited. Participants will be randomly assigned to one of three intervention groups (wine, grape, or juice) using a block randomization system stratified by sex to ensure a 1:1 balance across groups. The study will be partially blinded: participants will be unaware of the study hypothesis, but not the intervention, due to the nature of the matrices.
Not provided
Not provided
Masking will be partial: participants will be blind to hypotheses but not to the intervention (due to the nature of the matrices).
Not provided
| Grape | Dietary Supplement | Portion of fresh grapes providing an equivalent dose of tartaric acid as the wine, consumed under the same controlled conditions. |
|
| Juice | Dietary Supplement | 150 mL of grape juice standardized for tartaric acid content, ingested under identical conditions as the other arms. |
|
Maximum amount of tartaric acid excreted in urine, measured by LC-ESI-MS/MS. |
| 0-24 hours, collected in fractions: 0-4, 4-8, 8-12, and 12-24 h post-ingestion |
| Comparison of pharmacokinetic parameters by matrix | Comparison of Cmax, Tmax, AUC, and t1/2 between dietary matrices (wine, grape, grape juice) to assess matrix- and dose-dependence. | grape, grape juice) to assess matrix- and dose-dependence. 0-24 hours post-ingestion |
| D000088082 |
| Fermented Beverages |
| D000074421 | Fermented Foods |
| D019602 | Food and Beverages |